DPBR112, the first targeted therapy drug for lung cancer to be researched in Taiwan, has an estimated market value of NT$5 billion (US$171.7 million) per year, and could be approved for market launch within five years, the Ministry of Science and Technology said on Tuesday.
Sixty percent of patients with non-small cell lung cancer, who comprise 85 percent of lung cancer patients nationwide, require treatment via targeted therapy, said researcher Hsu Tzu-an (徐祖安) of the National Health Research Institutes’ (NHRI) Institute of Biotechnology and Pharmaceutical Research.
First-generation targeted therapy medication, such as Iressa and Tarceva, have been deemed ineffective, as patients’ easily develop a tolerance to them, Hsu said, adding that second-generation drugs, such as Afatinib, produce side effects.
Lung carcinoma patients in Taiwan, Japan, South Korea and China have a 50 to 60 percent higher chance of developing epidermal growth factor receptor (EFGR) gene mutations, Hsu said.
Four percent of EGFR gene mutations are identified as EGFR exon 20-mutated lung cancer, while another 4 percent develop human epidermal growth factor receptor 2 (HER2) mutations, Hsu said.
Available targeted therapy options abroad are unable to treat both mutation types, Hsu said.
The research team tested the drug against multiple mutated proteins and found that DBPR112 performs well in suppressing effects of wild-type EGFR and its mutated variants, Hsu said, adding that the team also found that DBPR112 has a higher oral absorption rate.
In the tests on mice, the team observed that test subjects seemed to have higher dosage tolerance with lowered toxicity and side effects, Hsu said, adding that the drug’s suppression rates of specific EGFR or HER2-mutated lung carcinoma cells were excellent.
Once DBPR112 launches, patients around the globe would be able to benefit from better targeted therapy medication, Hsu said.
The NHRI began researching the drug after receiving a NT$300 million grant from the ministry, and the seven-year research project completed its preclinical trials last year and is now conducting first-phase human clinical trials, Deputy Minister of Science and Technology Su Fong-chin (蘇芳慶) said.
Patents for the drug have been applied for and approved in Taiwan, the US, China, Japan and South Korea, Su said.
Su called on the biotech industry to support the trials and assist the government’s push for domestically produced pharmaceuticals.
Palauan President Surangel Whipps Jr arrived in Taiwan last night to kick off his first visit to the country since beginning his second term earlier this year. After arriving at Taoyuan International Airport at around 6:30 pm, Whipps and his delegation were welcomed by Minister of Foreign Affairs Lin Chia-lung (林佳龍). Speaking to gathered media, the Palauan leader said he was excited and honored to be back in Taiwan on his first state visit to Taiwan since he was sworn in this January. Among those traveling with Whipps is Minister of State Gustav N. Aitaro, Public Infrastructure
President William Lai (賴清德) yesterday thanked Palau for its continued support of Taiwan's international participation, as Taipei was once again excluded from the World Health Assembly (WHA) currently taking place in Switzerland. "Palau has never stopped voicing support for Taiwan" in the UN General Assembly, the WHO and other UN-affiliated agencies, Lai said during a bilateral meeting with visiting Palau President Surangel Whipps Jr. "We have been profoundly touched by these endorsements," Lai said, praising the Pacific island nation's firm support as "courageous." Lai's remarks came as Taiwan was excluded for the ninth consecutive year from the WHA, which is being held in
RESOLUTIONS DEBATE: Taiwan’s allies said that UN and WHA resolutions cited by China and other nations ‘do not determine Taiwan’s participation in WHO activities’ A proposal to invite Taiwan to this year’s World Health Assembly (WHA) was rejected on Monday, resulting in Taipei’s absence from the annual meeting for a ninth consecutive year, although partners spoke up for Taiwan’s participation at the first day of the meeting. The first agenda item after the opening was a “two-on-two debate” on a proposal to invite Taiwan to participate at the WHA as an observer. Similar to previous years, two countries made statements in favor of the proposal, while two others expressed their opposition. Philippine Secretary of Health Teodoro Herbosa, president of the 78th WHA, accepted the WHA General Committee’s
At least three people died and more than a dozen were injured yesterday afternoon when a vehicle struck a group of pedestrians in New Taipei City’s Sansia District (三峽). The incident happened at about 4pm when a car rammed into pedestrians at an intersection near Bei Da Elementary School. Witnesses said the sedan, being driven at a high speed, ran a red light, knocking scooters out of the way and hitting students crossing the road before careening into a median near the intersection of Guocheng and Guoguang streets. The incident resulted in three deaths and 13 injuries, including the driver, a 78-year-old man
RSS